Evidence map›Paper›PMID 38175855›Full record

ArticlePloS one2024

In-silico evaluation of natural alkaloids against the main protease and spike glycoprotein as potential therapeutic agents for SARS-CoV-2.

Mohibullah Shah, Ramsha Yamin, Iqra Ahmad, Gang Wu, Zainab Jahangir, Amen Shamim, Haq Nawaz, Umar Nishan, Riaz Ullah, Essam A Ali and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
11.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Mohibullah ShahDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.ORCID 0000-0001-6126-7102
Ramsha YaminDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Iqra AhmadDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Gang WuDepartment of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Zainab JahangirDepartment of Computer Science, University of Agriculture Faisalabad, Punjab, Pakistan.
Amen ShamimDepartment of Computer Science, University of Agriculture Faisalabad, Punjab, Pakistan.
Haq NawazDepartment of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan.
Umar NishanDepartment of Chemistry, Kohat University of Science & Technology, Kohat, Pakistan.ORCID 0000-0002-0106-3068
Riaz UllahDepartment of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Essam A AliDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
SheheryarDepartment of Biochemistry and Molecular Biology, Federal University of Ceara, Fortaleza, Brazil.
Ke ChenDepartment of Infectious Diseases, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Bahauddin Zakariya University · PKAffiliated Hospital of Southwest Medical University · CNKing Saud University · SAUniversity of Agriculture Faisalabad · PKKohat University of Science and Technology · PKUniversidade Federal do Ceará · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV-2) is the causative agent of COVID-19 pandemic, which has resulted in global fatalities since late December 2019. Alkaloids play a significant role in drug design for various antiviral diseases, which makes them viable candidates for treating COVID-19. To identify potential antiviral agents, 102 known alkaloids were subjected to docking studies against the two key targets of SARS-CoV-2, namely the spike glycoprotein and main protease. The spike glycoprotein is vital for mediating viral entry into host cells, and main protease plays a crucial role in viral replication; therefore, they serve as compelling targets for therapeutic intervention in combating the disease. From the selection of alkaloids, the top 6 dual inhibitory compounds, namely liensinine, neferine, isoliensinine, fangchinoline, emetine, and acrimarine F, emerged as lead compounds with favorable docked scores. Interestingly, most of them shared the bisbenzylisoquinoline alkaloid framework and belong to Nelumbo nucifera, commonly known as the lotus plant. Docking analysis was conducted by considering the key active site residues of the selected proteins. The stability of the top three ligands with the receptor proteins was further validated through dynamic simulation analysis. The leads underwent ADMET profiling, bioactivity score analysis, and evaluation of drug-likeness and physicochemical properties. Neferine demonstrated a particularly strong affinity for binding, with a docking score of -7.5025 kcal/mol for main protease and -10.0245 kcal/mol for spike glycoprotein, and therefore a strong interaction with both target proteins. Of the lead alkaloids, emetine and fangchinoline demonstrated the lowest toxicity and high LD50 values. These top alkaloids, may support the body's defense and reduce the symptoms by their numerous biological potentials, even though some properties naturally point to their direct antiviral nature. These findings demonstrate the promising anti-COVID-19 properties of the six selected alkaloids, making them potential candidates for drug design. This study will be beneficial in effective drug discovery and design against COVID-19 with negligible side effects.

Indexed as

AlkaloidsAntiviral AgentsProtease InhibitorsSARS-CoV-2Spike Glycoprotein, CoronavirusCOVID-19EmetineHumansMolecular Docking SimulationMolecular Dynamics SimulationPeptide HydrolasesAlkaloidsAntiviral AgentsEmetinePeptide HydrolasesProtease InhibitorsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID38175855
PMCPMC10766191
OpenAlexW4390646002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.